Maelor with Charts

>Wiganer

You may have made the right decision and best of luck to you but I dont think I will join you as it will take a long time (IMO) for Ark to make a significant return whereas MLR could make a substantial return - as you appear to accept - this year.

Market Cap 139m with 127m shares in issue. Just how many unmet clinical needs within vascular disease and cancer are there? Whilst they may have patents have their products gone through the strict drug testing procedures in the US. We all know that the drug regime in the USA is part of their protectionist policies.

Still to each his own.


Could not find the company web page but took this from an announcement last year.

Ark Therapeutics Group plc

Ark is an emerging healthcare group (the “Group”) entering the commercialisation phase, with one product introduced into hospitals and three further lead products in late stage clinical development. Capitalising on over ten years of research in vascular biology and gene-based medicine, Ark has a balanced portfolio of proprietary healthcare products targeted at specific unmet clinical needs within vascular disease and cancer. These are large and growing markets, where opportunities exist for effective new products to generate significant revenues.

Ark’s products are sourced from related but largely non-dependent technologies within the Group and have been selected to enable the Company to take each product through development and to benefit from Orphan Drug Status and/or Fast Track Designation, as appropriate. The Group generally retains ownership of its product candidates throughout clinical development. Ark has secured patents or has patent applications pending for all its lead products in principal pharmaceutical markets and retains the right to market its lead products in the key North American and European markets.

Ark has its origins in businesses established in the mid-1990s by Professor John Martin and Mr Stephen Barker of University College London and Professor Seppo Ylä-Herttuala of the AI Virtanen Institute at the University of Kuopio, Finland, all of whom play leading roles in the Company's research and development programmes.